One of the more successful combinations for AML was represented by HMA plus venetoclax (VEN), the latter being a BCL2 inhibitor first used for relapse/refractory (R/R) chronic lymphocytic leukemia (CLL). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.